[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623051":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":60,"collaborators":11,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":11,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":11,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Cartesian Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Decartes-08","EXPERIMENTAL",null,[13],"Drug: Descartes-08",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Other: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Descartes-08","Autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA)",[9],{"type":26,"name":15,"description":27,"armGroupLabels":28,"otherNames":11},"OTHER","Plasma-Lyte",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Vera MD","CONTACT","6172318085","trials@cartesiantx.com",[36,50],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":11},"T13","RECRUITING","Chapel Hill","North Carolina","27599","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-79.05584,35.9132,{"lat":48,"lon":47},{"facility":51,"status":38,"city":52,"state":53,"zip":54,"country":42,"countryCode":43,"cosmosGeoPoint":55,"geoPoint":59,"contacts":11},"T23","Austin","Texas","78759",{"type":45,"coordinates":56},[57,58],-97.74306,30.26715,{"lat":58,"lon":57},{"type":61,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623051","phase-2-descartes-08-in-autoantibody-myositis-100623051",false,"NCT07391605","Descartes-08 in Autoantibody Myositis","A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome","Inclusion Criteria:\n\n* Confirmed diagnosis of one of the following:\n\nDermatomyositis (DM): Probability score ≥55% on the 2017 EULAR\u002FACR (European Alliance of Associations of Rheumatology\u002F American College of Rheumatology) criteria for classification of dermatomyositis (corresponding to diagnosis of 'probable or definite' DM). OR Antisynthetase Syndrome (ASyS): Diagnosis based on ACR\u002FEULAR Classification Criteria (1).\"\n\n* Participants must have dermatomyositis or antisynthetase syndrome with muscle and\u002For skin involvement.\n* Refractory or intolerance to standard therapy.\n* Stable background immunosuppressive therapy for ≥8 weeks.\n* Adequate hematologic, renal, hepatic, and pulmonary function (SpO₂ ≥92% on room air).\n* Informed consent, compliance with visits, contraception, and vaccinations required.\n\nExclusion Criteria:\n\n* Isolated interstitial lung disease (ILD) without muscle or skin involvement\n\n  * Severe irreversible muscle damage or advanced weakness (e.g., wheelchair-bound).\n  * Interstitial lung disease (ILD) requiring oxygen, severe pulmonary impairment (FVC ≤45%, DLCO ≤40%), or pulmonary hypertension.\n  * Other inflammatory myopathies (PM, IMNM, IBM, cancer- or drug-induced myositis, overlap myositis except Sjögren's).\n  * Other severe neuromuscular, cardiac, pulmonary, or systemic autoimmune diseases requiring immunosuppression.\n  * Significant uncontrolled chronic illnesses or psychiatric conditions interfering with participation.\n  * Pregnancy or lactation.\n  * Recent use of prohibited immunosuppressants\u002Fbiologics or investigational agents (per washout periods).\n  * Live vaccination within 4 weeks.\n  * History of primary immunodeficiency, organ or bone marrow transplant.\n  * Active or uncontrolled infections: HBV, HCV, HIV, tuberculosis, or recurrent\u002Fsevere infections.","ALL","18 Years",{"count":72,"type":73},60,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).",[79],"Antisynthetase Syndrome",[81,82,83,84,85],"MYOSITIS","DESCARTES-08","MRNA CAR-T","TOTAL IMPROVEMENT SCORES","CDASI","2026-04-22",{"date":88,"type":89},"2026-04-23","ACTUAL",{"date":91,"type":73},"2026-04-28",{"date":93,"type":73},"2028-05",{"name":5,"class":6},2]